Tone-Up Ampoule at Two Weeks: Understanding the Conditions Behind a 27.37% Mean

The study ran from May 26 to June 12, 2026, and the report was issued June 26. The sample name was NARINFLA Repair Tone-up Apoule and the sample number PM-26SA-947. We retain the report’s spelling as a study identifier, rather than reinterpret it as a new product name.^[S1]

Participants averaged 50.4 years, and all 20 completed the study with no withdrawals. There was 1 participant in her 30s, 8 in their 40s, 10 in their 50s, and 1 in her 60s. Several ages were included, but this was not a large sample representative of every age.

Participants applied an appropriate amount to the face morning and evening. We do not convert “appropriate amount” into invented drops or milliliters. The amount used in an everyday routine can depend on product directions and feel.

A reader’s skin may differ from the study’s eligibility conditions. The study did not establish the same results for people with skin disease or allergies, immediately after procedures, or during pregnancy. These boundaries should be read before the number.

The check compared the methods and appendix data, not just the summary. The sample identifier links the evidence to the tested finished product. “Tone-up” in a name does not mean an immediate makeup-like color effect was tested. The question was how pigmentation area in a selected facial region changed after two weeks—not immediate complexion changes or the full scope of wrinkle-care functionality.^[S1]

The 30-minute acclimation and temperature/humidity conditions standardize before-and-after measurements. They are not instructions that users must reproduce at home for a benefit. A phone photograph taken immediately after application cannot be compared in the same units with the study instrument. We keep “appropriate amount” from the source rather than invent a study-validated number of drops.^[S1]

The instrument measured Hyper-concentration area under facial Pigmentation. The unit was square millimeters (mm²), and a lower value was interpreted as improvement. Calling it a number of melasma spots or melanin cells would misdescribe the method.^[S1]

Mean baseline area was 190.626mm² and the two-week mean 138.629mm², a mean change of −51.997mm². Standard deviations were 68.268 and 52.856, respectively, also showing differences between participants’ starting conditions.

The reported rate is 27.370%, the mean after calculating “(baseline − two-week value) ÷ baseline × 100” for each person. A percentage calculated from the two group mean areas can differ slightly. A ratio of means and a mean of ratios are not necessarily equal.

The 9.314 standard deviation describes dispersion of participant improvement rates. It is not an expected range of “mean ± 9.314” for everyone or a probability that a reader’s result falls within it. We do not create a prediction interval absent from the source.

Each individual calculation is (baseline area − two-week area) ÷ baseline area × 100. Each person’s own baseline is the denominator, expressing changes relative to different starting areas. Dividing the overall mean areas, 190.626mm² and 138.629mm², uses different weighting, so it does not replace the reported mean rate of 27.370%. A small difference between these averages is not itself an error.^[S1]

Recalculating the 20 appendix rates displayed to three decimal places gives an arithmetic mean of 27.3705%, while the report states 27.370%. Displayed rounded values alone cannot establish the precision or truncation method of the original calculation, so the main figure remains the report’s 27.370%. The maximum and minimum match the same appendix’s 45.019% and 8.681%. We retain the limit of the displayed precision rather than make the number look more exact.^[S1]

The largest improvement rate was 45.019% and the smallest 8.681%. Both came from the same study; selecting only one changes the impression. We present the mean with the range so the greatest change is not mistaken for a typical result.^[S1]

This range is the minimum and maximum observed in these 20 participants. It does not promise at least 8.681% improvement for the next user, or establish 45.019% as a guaranteed maximum effect. A different sample can produce a different range.

Results are identified only by participant number, without names, initials, or face photographs. Transparent explanation of numbers differs from disclosure of personal records. The report also restricts third-party disclosure, so permission to release the full original requires separate review.

Read the mean first and the range second. If an advertisement emphasizes a maximum, ask “maximum among how many, what was the mean, and was it the same measure?” Avoid comparing the largest numbers from different studies.

NARINFLA starts its explanation with the mean and uses the maximum to describe individual variation. This does not diminish positive results; it clarifies the roles of different numbers. 45.019% alone sets expectations at the maximum, whereas 27.370% with the range shows different responses over the same period. Meaningful studies do not require every participant to have an identical result.

The report used a paired-samples t-test and judged differences significant at p<0.05. The displayed p-value 0.000 does not mean a probability of exactly zero; we retain the report’s conclusion of a significant before-and-after difference at p<0.05.^[S1]

Comparing the same person before and after accounts for different starting conditions, but it is not comparison with a non-use group. This design cannot fully separate effects of season, UV exposure, other routine changes, and measurement variation.

We therefore distinguish “the measured value decreased after product use” from “the product was the sole cause.” No control group does not invalidate the observation, but neither does it permit unrestricted claims.

Korean brightening-functional status and a separate human-use study serve different roles. The regulatory system concerns the corresponding cosmetic claim; this study examined pigment-area changes under specified conditions. One number is not a performance score for the entire functional status and does not imply U.S. FDA approval.^[S3][S4]

The results table shows p=0.000 to three decimal places, not an actual probability of exactly zero. We retain p<0.05 from the summary and decision threshold. Pairing two time points for each person considers starting differences, but is not a parallel comparison with seasonal changes in an untreated control group.^[S1]

In particular, 7% tranexamic acid and 5% niacinamide describe the finished formula. The study tested an ampoule containing both, not an otherwise identical formula without tranexamic acid or a different concentration. Do not label 27.370% as either ingredient’s effect rate or claim that combining them doubled the effect. We provide composition and finished-product results together while keeping causal explanations within the design’s scope.^[S1][S2]

The report states that no particular skin adverse reactions occurred during the study. Keeping the 20-participant, two-week scope visible recalls both the no-skin-allergy eligibility and the short observation period.^[S1]

The item “I feel my melasma and dark spots have improved” averaged 4.80, with 100% scoring 3 or above. A score of 3 includes neutral. There were 17 strongly agree, 2 agree, and 1 neutral responses—not “everyone was highly satisfied.”

Instrument measurements and perception surveys are different data. One records pigment area; the other records subjective responses. Combining them into “100% clinical satisfaction efficacy” obscures what was measured.

No reactions among the study participants does not eliminate possible redness, itching, or swelling with a new product. AAD advises testing a small inner-arm area twice daily for 7–10 days and washing off and discontinuing if a reaction occurs.^[S5]

The report measured only weeks 0 and 2. It does not answer whether a change appeared on day 3, persisted for months, or reversed after stopping. The two-week result is not a promise for every duration.

Start personal notes with product name, starting date, frequency, other newly introduced products, and stinging. This is a practical routine-review suggestion, not a clinical test. Changing several products in one week makes causes harder to separate; one change at a time is easier to observe.

Natural-light photographs cannot substitute for instrument values. Lighting, camera processing, and distance can alter apparent color. Personal record photos are possible, but should not become calculated clinical improvement rates or advertising before-and-after evidence.

If a spot thought to be melasma changes rapidly, bleeds, or changes shape, seek advice from a qualified local healthcare professional before evaluating cosmetics. Measuring facial pigmentation area is not diagnosis of an individual spot. For ingredient principles, see the niacinamide evidence map (Korean original); for selection, see the two-ampoule choice guide (Korean original).

The 17 strongly agree and 2 agree responses total 19 in the two positive categories; the remaining participant was neutral. The report defined a positive response as 3 or above, supporting its 100% figure, but “everyone was satisfied” changes the scale’s meaning. We give the distribution and do not add it to the instrumental improvement rate.^[S1]

For personal observation, record comfortable daily use and continuation without stinging rather than attempting an improvement-rate calculation. Even same-lighting photos do not replace instrument pigmentation-area measurements. Participants were adults without skin disease or allergies; that observation cannot establish safety for sensitive skin, pregnancy, breastfeeding, or immediately after a procedure. In important individual circumstances, current product directions and a qualified local clinician take priority.